EDUCATIONAL ARTICLE
Oregano oil: uses, potential benefits and human consumption
Oregano oil is being investigated for potential biological properties. Here we summarise only three studies by authors affiliated with recognised universities, distinguishing essential oil from extract and laboratory findings from results in people.
Educational information. These studies did not test XTO's product or establish its suitability for human consumption. No doses or ingestion recommendations are provided.

1. Johns Hopkins and Harvard Medical School: antibacterial activity
Feng and colleagues tested essential oils against Borrelia burgdorferi cultures. Oregano oil showed activity in that laboratory model. Authors included researchers from Johns Hopkins and a co-author affiliated with Harvard Medical School. [1]
This was not a patient trial. It does not establish that swallowing oregano oil treats Lyme disease. [1]
2. Georgetown: experimental antifungal activity
Manohar and colleagues studied oregano oil against Candida albicans in cultures and mice. They found antifungal activity in those models. The main published affiliation is Georgetown University Medical Center. [2]
This is research into potential applications, not evidence of a cure for fungal infections in people. [2]
3. University of Helsinki: what happened in people
Nurmi and colleagues conducted a four-week randomised trial with 45 healthy men. They tested a drink with oregano extract, not essential oil. Phenolic-compound excretion increased, but blood lipids and markers of lipid oxidation did not significantly improve. [3]
This study therefore does not establish a clinical antioxidant benefit of oregano oil or justify recommending its ingestion. [3]
4. What these potential benefits mean
The results support further research. Two studies are preclinical, while the third used a preparation different from essential oil. None validates XTO's oil or establishes a human-use dose.
Universities are identified through author affiliations. Naming them does not mean they endorse, certify or recommend a commercial product.
5. What remains to be verified for XTO's oil
XTO is preparing B2B requests for pure/undiluted and diluted options. Batch documentation and assessment of suitability for the intended use remain pending. For the diluted option, carrier and final concentration are also outstanding.
The word “natural,” presentation or a declared percentage cannot replace that review. Consult a health professional about health-related use. This article contains no consumption regimen.
For a commercial inquiry, state intended application, quantity, packing and destination. Price, origin and availability remain subject to confirmation. Dried oregano remains XTO's first commercial priority.
B2B inquiry for documentation review; not a consumption recommendation.
Only three selected studies
- Feng et al. (2017) — Essential oils and Borrelia, in-vitro study — Johns Hopkins University; co-author affiliated with Harvard Medical School · DOI 10.3389/fmed.2017.00169
- Manohar et al. (2001) — Oregano oil against Candida — Georgetown University Medical Center · DOI 10.1023/A:1013311632207
- Nurmi et al. (2006) — Human trial with oregano extract — University of Helsinki · DOI 10.1021/jf0608928
Editorial selection by XTO GROUP INC. Author affiliations and publications checked on November 8, 2026. Not an exhaustive review or a medical recommendation.
